Table 1. Characteristics of the 14 selected studies in this meta-analysis.
| Author (year) | No. of patients | No. of patients with HTN (%) | Gender (M/F) | Line of treatment | Bevacizumab dose | Chemotherapy regiments | HTN criteria | Cut-off point | Median PFS (months) HTN/non-HTN | Median OS (months) HTN/non-HTN | ORR (%) HTN/non-HTN |
| Ryanne (2009) | 84 | 36 (42.9) | 42/42 | First | NA | NA | CTC AE V3.0 | Grade = 0 | NA | NA | NA |
| Scartozzi (2009) | 39 | 8 (20.5) | 25/14 | First | 5 mg/kg/2w | FOLFIRI | CTC AE V2.0 | Grade < 2 | 14.5/3.1 | NA/15.1 | 75/32 |
| De Stefano (2011) | 74 | 13 (17.6) | 42/32 | First | 5 mg/kg/2w or 7.5 mg/kg/3w | FOLFIRI, FOLFOX, XELOX, XELIRI, FOLFOXIRI | CTC AE V3.0 | Grade = 0 | 15.1/8.3 | 35.5/26.7 | 84.6/42.6 |
| Mir (2011) | 119 | 65 (54.6) | 63/56 | NA | 2.5 mg/kg/w | 5-FU-based | CTC AE V3.0 | Grade = 0 | NA | NA | 76.9/79.6 |
| Osterlund (2011) | 101 | 57 (56.4) | 54/47 | Combined | 5 mg/kg/2w or 7.5 mg/kg/3w | FOLFIRI, irinotecan-, oxaliplatin- or 5-FU-based | CTC AE V3.0 | Grade = 0 | 10.5/5.3 | 25.8/11.7 | 52.6/45.5 |
| Dewdney (2012) | 45 | 7 (15.6) | NA | First | 7.5 mg/kg/3w | CAPOX | CTC AE V3.0 | Grade = 0 | NA | NA | 71/78 |
| Budai (2013) | 232 | NA | 126/106 | First | 5 mg/kg/2w | modified FOLFIRI | CTC AE V3.0 | Grade ≤ 1 | NA | NA | NA |
| Hurwitz (2013) | 402 | NA | 237/165 | First | 5 mg/kg/2w | IFL | CTC AE V2.0 | SBP/DBP increase 20/10 mmHg | NA | NA | NA |
| Hurwitz (2013) | 699 | NA | 418/281 | First | 5 mg/kg/2w | FOLFOX-4 | CTC AE V3.0 | SBP/DBP increase 20/10 mmHg | NA | NA | NA |
| Morita (2013) | 60 | 16 (26.7) | 38/22 | First | 5 mg/kg/2w | mFOLFOX6, FOLFIRI, sLV5FU2, XELOX | CTC AE V4.0 | Grade ≤ 2 | NA | NA | NA |
| Tahover (2013) | 181 | 81 (44.8) | 95/86 | First | 2.5 mg/kg/w | oxaliplatin, 5FU combination, irinotecan, 5FU combination, both combinations | CTC AE V4.0 | Grade ≤ 1 | 17.2/29.9 | 36.8/NA | NA |
| Khoja (2014) | 50 | 7 (14) | NA | Combined | NA | tyrosine kinase inhibitor (TKI) | CTC AE V3.0 | Grade ≤ 1 | 10.9/9.4 | 25.2/21.6 | NA |
| Feliu J (2015) | 127 | 20 (15.7) | 78/49 | NA | 7.5 mg/kg/3w | capecitabine in BECA, oxaliplatin, capecitabine in BECOX | CTC AE V2.0 | Grade = 0 | NA | NA/16.9 | NA |
| de Sousa (2016) | 79 | 41 (51.9) | 53/26 | First | 5 mg/kg/2w | FOLFIRI or FOLFOX regimen | CTC AE V4.0 | Grade ≤ 1 | NA | 33/21 | NA |
Abbreviations: HTN: hypertension; M: male; F: female; NA: not available; SBP: systolic blood pressure; DBP: diastolic blood pressure; ORR: objective response rate; OS: overall survival; PFS: progression free survival; CTC: common terminology criteria; AE: adverse events.